期刊
SURVEY OF OPHTHALMOLOGY
卷 59, 期 1, 页码 30-46出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.survophthal.2013.03.007
关键词
Coats disease; type 1 idiopathic macular; telangiectasia; intravitreal bevacizumab; Leber multiple miliary aneurysms; retinal vascular disease
资金
- Research to Prevent Blindness, Inc., New York, NY
- Ayers Foundation, Parson, TN
Since its original description in 1908, Coats disease has been recognized as an idiopathic cause of severe vision loss with a remarkable diversity in clinical presentation and morphology. Key clinical and imaging variables are helpful in differentiating Coats disease from life-threatening malignancies, and proper management revolves around a thorough knowledge of the differential diagnosis. Despite significant advancement in scientific understanding of the disease process and clinical spectrum, the underlying etiology remains obscure, and both primary and secondary forms are recognized. With the development of anti-VEGF therapy, vitreoretinal specialists have a new, effective adjunct to the clinical management of exudates, macular edema, and serous retinal detachment. We highlight the history, diagnostic challenges, evolving clinical spectrum, and current management of Coats disease. (C) 2014 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据